Acelyrin, Inc.(SLRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLRN Acelyrin, Inc.

Market Closed 05-17 16:00:00 EDT

4.39

-0.24

-5.18%

盘后4.39

+0.000.00%

18:03 EDT

High4.68	Low4.37	Vol742.13K
Open4.67	D1 Closing4.63	Amplitude6.70%
Mkt Cap434.73M	Tradable Cap283.66M	Total Shares99.03M
T/O3.31M	T/O Rate1.15%	Tradable Shares64.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SLRN","market":"US","secType":"STK","nameCN":"Acelyrin, Inc.","latestPrice":4.39,"timestamp":1715976000000,"preClose":4.63,"halted":0,"volume":742134,"hourTrading":{"tag":"盘后","latestPrice":4.39,"preClose":4.39,"latestTime":"18:03 EDT","volume":6317,"amount":27731.6,"timestamp":1715983400011},"delay":0,"floatShares":64614819,"shares":99026983,"eps":-2.680253,"marketStatus":"Market Closed","change":-0.24,"latestTime":"05-17 16:00:00 EDT","open":4.67,"high":4.68,"low":4.37,"amount":3307720.92336,"amplitude":0.066955,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.680253,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1716192000000},"marketStatusCode":7,"adr":0,"listingDate":1683259200000,"exchange":"NASDAQ","adjPreClose":4.63,"postHourTrading":{"tag":"盘后","latestPrice":4.39,"preClose":4.39,"latestTime":"18:03 EDT","volume":6317,"amount":27731.6,"timestamp":1715983400011},"volumeRatio":1.1670634278719347},"requestUrl":"/m/hq/s/SLRN","defaultTab":"news","newsList":[{"id":"2434332185","title":"MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2434332185","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434332185?lang=en_us&edition=fundamental","pubTime":"2024-05-12 20:37","pubTimestamp":1715517469,"startTime":"0","endTime":"0","summary":"MoonLake develops sonelokimab, targeting large markets like psoriasis and hidradenitis suppurativa, with promising Phase 2 data.Despite a competitive landscape with established IL-17 inhibitors, MoonL","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1393307209/image_1393307209.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1393307209/image_1393307209.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4692553-moonlake-immunotherapeutics-competitive-edge-in-autoimmune-market-expansion","is_publish_highlight":false,"gpt_icon":0},{"id":"2434108790","title":"Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and ACELYRIN, INC. (SLRN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434108790","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434108790?lang=en_us&edition=fundamental","pubTime":"2024-05-10 00:30","pubTimestamp":1715272219,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Moderna (MRNA – Research Report) and ACELYRIN, INC...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-moderna-mrna-and-acelyrin-inc-slrn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-moderna-mrna-and-acelyrin-inc-slrn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434823010","title":"Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), ACELYRIN, INC. (SLRN) and Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434823010","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434823010?lang=en_us&edition=fundamental","pubTime":"2024-05-10 00:20","pubTimestamp":1715271611,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phathom Pharmaceuticals (PHAT – Research Report), ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phathom-pharmaceuticals-phat-acelyrin-inc-slrn-and-moderna-mrna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phathom-pharmaceuticals-phat-acelyrin-inc-slrn-and-moderna-mrna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434721099","title":"ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2434721099","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2434721099?lang=en_us&edition=fundamental","pubTime":"2024-05-09 20:01","pubTimestamp":1715256060,"startTime":"0","endTime":"0","summary":"Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by end of third and fourth quarter of 2024, respectively. Reported positive proof-of-concept for lonigutamab in thyroid eye disease patients and positive top-line Phase 2b/3 data for izokibep in psoriatic arthritis. Cash, cash equivalents, and short-term marketable securities at March 31, 2024 of $678.5 million. ACELYRIN expects to report cash, cash equivalents, and short-term marketable securities of $678.5 million at March 31, 2024.The company previously stated that its cash position is expected to fund operations into 2026. ACELYRIN is reiterating","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.Rv9amMmsaBYxL9emXDZyA--~B/aD00MTt3PTMwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4f585961a91209275f71ace995ce92dd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.Rv9amMmsaBYxL9emXDZyA--~B/aD00MTt3PTMwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4f585961a91209275f71ace995ce92dd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acelyrin-inc-provides-business-highlights-120100654.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425530947","title":"North American Morning Briefing: Investors on Edge as High-Stakes Jobs Report Awaited","url":"https://stock-news.laohu8.com/highlight/detail?id=2425530947","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2425530947?lang=en_us&edition=fundamental","pubTime":"2024-04-05 18:08","pubTimestamp":1712311680,"startTime":"0","endTime":"0","summary":"Stock futures pointed to a slight rebound on Friday ahead of the jobs report for March.The stakes are high for a stock-market rally that's faltered this week as investors assess the likelihood of rate cuts by the Federal Reserve later this year.Economists surveyed by the Wall Street Journal, on average, look for nonfarm payrolls to show a rise of 200,000 in March, with the unemployment rate expected to tick down from 3.9% to 3.8%. Growth in hourly wages is expected to slow to a year-over-year rate of 4.1%, from 4.3% in February.\"Investors are on edge the Fed may delay rate cuts from June until later in the summer [or late in 2024] if we get another hot employment report, \" it said.In particular, Neel Kashkari said if inflation continued to move sideways he could question whether rate cuts were needed at all. This comment was notable given the latest oil-price rise, Deutsche Bank said.This would add to recent signs that the U.S. jobs market is softening, leaving the Federal Reserve \"in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2422923261","title":"Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2422923261","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2422923261?lang=en_us&edition=fundamental","pubTime":"2024-03-28 04:01","pubTimestamp":1711569660,"startTime":"0","endTime":"0","summary":"Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc.Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026. Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027. Dr. Neil continued, “I want to thank Patrick Crutcher and his team at AlmataBio for their great work in identifying and bringing this potentially best-in-class molecule forward. Mr. Crutcher has a long history of successful biotech entrepreneurship and identifying high quali","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d2A3qC7SG8Tok_kXv5MHIw--~B/aD0xMjIxO3c9MjI2OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4ff929bac6afa20af6c287a4c754c6ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d2A3qC7SG8Tok_kXv5MHIw--~B/aD0xMjIxO3c9MjI2OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4ff929bac6afa20af6c287a4c754c6ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avalo-acquires-anti-il-1-200100092.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421819743","title":"Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2421819743","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2421819743?lang=en_us&edition=fundamental","pubTime":"2024-03-22 21:30","pubTimestamp":1711114241,"startTime":"0","endTime":"0","summary":"Tourmaline Bio, Inc.'s share price dropped by 37% after Chugai's Enspryng, an IL-6 blocker, failed to meet expectations in a study on myasthenia gravis.Tourmaline is developing TOUR006, its own IL-6 b","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1079127056/image_1079127056.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1079127056/image_1079127056.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4679896-tourmaline-bio-sinking-on-rivals-stodgy-data-im-slightly-bearish","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acelyrin.com","stockEarnings":[{"period":"1week","weight":-0.062},{"period":"1month","weight":-0.1255},{"period":"3month","weight":-0.4743},{"period":"6month","weight":-0.5006},{"period":"1year","weight":-0.8066},{"period":"ytd","weight":-0.4115}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.","exchange":"NASDAQ","name":"Acelyrin, Inc.","nameEN":"Acelyrin, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acelyrin, Inc.(SLRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Acelyrin, Inc.(SLRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Acelyrin, Inc.,SLRN,Acelyrin, Inc.股票,Acelyrin, Inc.股票老虎,Acelyrin, Inc.股票老虎国际,Acelyrin, Inc.行情,Acelyrin, Inc.股票行情,Acelyrin, Inc.股价,Acelyrin, Inc.股市,Acelyrin, Inc.股票价格,Acelyrin, Inc.股票交易,Acelyrin, Inc.股票购买,Acelyrin, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acelyrin, Inc.(SLRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Acelyrin, Inc.(SLRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}